Table 1.
Patient and pathology characteristics of NMIBCa patients who received full or reduced dose induction BCG before and after propensity score matching.
| Before Matching | After Matching | ||||||
|---|---|---|---|---|---|---|---|
| Full Dose (n = 83) |
Reduced Dose (n = 56) |
p | Full Dose (n = 56) |
Reduced Dose (n = 56) |
p | ||
| Age (years), median | 69.9 | 70.8 | 0.60 | 71.1 | 70.8 | 0.61 | |
| Sex, n male (% male) | 64 (77.1%) | 45 (80.4) | 0.91 | 46 (82.1%) | 45 (80.4%) | 1.0 | |
| Ethnicity | White, n (%) | 66 (79.5%) | 41 (73.2%) | 0.67 | 46 (82.1%) | 41 (73.2%) | 0.52 |
| Black, n (%) | 13 (15.7%) | 11 (19.6%) | 7 (12.5%) | 11 (19.6%) | |||
| Other, n (%) | 4 (4.8%) | 4 (7.1%) | 3 (5.4%) | 4 (7.1%) | |||
| Prior Bladder Cancer, n (%) | 21 (25.3%) | 6 (10.7%) | 0.05 | 6 (10.7%) | 6 (10.7%) | 1.0 | |
| Initial Pathology (%) | Ta, n (%) | 36 (43.4%) | 17 (30.3%) | 0.28 | 17 (30.3%) | 17 (30.4%) | 0.95 |
| CIS, n (%) | 14 (16.9%) | 8 (14.2%) | 10 (17.8%) | 8 (14.2%) | |||
| T1, n (%) | 28 (33.7%) | 26 (46.4%) | 25 (44.6%) | 26 (46.4%) | |||
| Mixed, n (%) | 4 (4.8%) | 5 (8.9%) | 4 (7.1%) | 5 (8.9%) | |||